Investigational New Drugs

Papers
(The H4-Index of Investigational New Drugs is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Improved delivery of Mcl-1 and survivin siRNA combination in breast cancer cells with additive siRNA complexes62
Direct functional HOXA9/DNA-binding competitors versus epigenetic inhibitors of HOXA9 expression on cell proliferation, death and differentiation processes in the model of MLL-rearranged acute myeloid50
MLN0905, a new inhibitor of Polo-like kinase 1 (PLK1), enhances the efficiency of lenalidomide in promoting the apoptosis of multiple myeloma cell lines41
Safety and efficacy of apatinib in combination with chemotherapy with or without immunotherapy versus chemotherapy alone as first-line treatment for advanced gastric cancer39
Research progress on cancer-related epigenetic switches34
Enhanced antitumor and anti-metastasis by VEGFR2-targeted doxorubicin immunoliposome synergy with NK cell activation31
Neoadjuvant immunochemotherapy in locally advanced laryngeal cancer and hypopharyngeal cancer: higher objective response rate and organ-preservation rate30
Clinical features, treatment and outcomes of dabrafenib-associated uveitis28
The ATR inhibitor berzosertib acts as a radio- and chemosensitizer in head and neck squamous cell carcinoma cell lines27
RNA silencing of GM-CSF in CAR-T cells reduces the secretion of multiple inflammatory cytokines27
Idarubicin versus epirubicin in drug-eluting beads-transarterial chemoembolization for treating hepatocellular carcinoma: A real-world retrospective study26
Gefitinib, an effective treatment option for patients with pulmonary enteric adenocarcinoma harboring compound EGFR L858R and A871G mutation25
The analysis of molecular classification of pulmonary neuroendocrine tumors and relationship between YAP1 and efficacy24
Synergistic antitumor effect of MK-1775 and CUDC-907 against prostate cancer24
Efficacy of salvage therapies after failure of adjuvant anti-PD-1 monotherapy for melanoma in the Chinese population: a multi-institutional cohort study23
MY11 exerts antitumor effects through activation of the NF-κB/PUMA signaling pathway in breast cancer22
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [14C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healt21
The role of dinutuximab beta with beta cell function, apoptosis, and proliferation: new approaches to proteomic analysis of insulinoma21
A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with Melanoma19
0.097454071044922